

Sun Pharmaceutical Industries Ltd.

Sun House, Plot No. 201 B/1,
Western Express Highway, Goregaon (E),
Mumbai - 400 063, Maharashtra, INDIA.
Tel. : (91-22) 4324 4324
Fax : (91-22) 4324 4343
Website : www.sunpharma.com
CIN : L24230GJ1993PLC019050



March 12, 2020

BSE Limited,
Market Operations Dept.
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001,
Maharashtra, India.
Scrip Code: 524715

National Stock Exchange of India Limited,
Exchange Plaza, 5th Floor,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (East), Mumbai – 400 051,
Maharashtra, India.
NSE Code – SUNPHARMA

Dear Sir/Madam,

Subject: Intimation of Board Meeting scheduled to be held on Tuesday, March 17, 2020 to consider *inter alia*, the proposal for buy-back of equity shares and intimation of closure of the trading window.

As required under Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, we wish to intimate you that the meeting of Board of Directors of the Company is scheduled to be held on Tuesday, March 17, 2020, to consider and if deemed fit, to approve, *inter alia*, the proposal for buy-back of fully paid-up equity shares of the Company, which would include maximum amount, maximum number of equity shares, mode of buy-back and other matters incidental thereto in accordance with the provisions of Section 68, 69 and 70 of the Companies Act, 2013, read with rules made thereto and Securities and Exchange Board of India (Buy-back of Securities) Regulations, 2018.

In this connection, as per the Company's code of conduct for prevention of insider trading, the trading window for dealing or trading in securities of the Company will remain closed with immediate effect for all directors, designated persons and insiders and shall re-open after the expiry of 48 hours after the conclusion of the aforesaid Board Meeting.

Request you to kindly take this on record and disseminate the same.

Yours faithfully,

For Sun Pharmaceutical Industries Limited

C. S. Muralidharan
Chief Financial Officer